SN
Shabnam Naseer
Internal Medicine
Credentials: ·
History
Infectious Disease
Internal Medicine
Research
US Food and Drug Administration (FDA): Benefit-Risk Considerations for Cefiderocol (Fetroja®)
Clinical Infectious Diseases · 2021 · First of 11 authors · 48 citations
Cefiderocol Dosing for Patients Receiving Continuous Renal Replacement Therapy
Clinical Pharmacology & Therapeutics · 2022 · 11 citations
- DI
2 papers
- EW
2 papers
- SN
2 papers
- JF
1 paper